Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
82.91
+0.61 (+0.74%)
Streaming Delayed Price
Updated: 1:57 PM EST, Jan 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
June 28, 2023
With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors.
Via
MarketBeat
Topics
Initial Public Offering
Where Protagonist Therapeutics Stands With Analysts
↗
June 12, 2023
Via
Benzinga
Chart Of The Day: Protagonist Therapeutics - Wide Opinions
↗
June 09, 2023
Via
Talk Markets
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
June 09, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
June 06, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
June 01, 2023
Via
Investor Brand Network
Protagonist Therapeutics: Q1 Earnings Insights
↗
May 04, 2023
Via
Benzinga
4 Analysts Have This to Say About Protagonist Therapeutics
↗
April 27, 2023
Via
Benzinga
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
↗
March 15, 2023
Via
Benzinga
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 01, 2023
Via
ACCESSWIRE
Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
↗
May 12, 2023
Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of
Via
Benzinga
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
↗
May 05, 2023
The company is targeting psoriasis with a first-ever mechanism that could rival leaders.
Via
Investor's Business Daily
Why Shares of Protagonist Therapeutics Rose This Week
↗
April 20, 2023
The company's lead pipeline candidate is making news.
Via
The Motley Fool
Why Protagonist Therapeutics Shares Are Nosediving
↗
April 05, 2023
Protagonist Therapeutics Inc (NASDAQ: PTGX) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
April 05, 2023
Via
Benzinga
Why Protagonist Therapeutics Shares Are Trading Higher Today
↗
March 07, 2023
Via
Benzinga
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
April 04, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
April 04, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 15, 2023
Via
ACCESSWIRE
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
March 15, 2023
Via
ACCESSWIRE
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
↗
March 14, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
March 07, 2023
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
March 07, 2023
Via
Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
↗
March 07, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Top 5 Health Care Stocks That May Collapse In February
↗
February 13, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Protagonist Therapeutics Earnings Perspective: Return On Capital Employed
↗
August 25, 2022
Protagonist Therapeutics (NASDAQ:PTGX) brought in sales totaling $859 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 96.07%, resulting in a loss of $41.04...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
July 05, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million.
Via
Benzinga
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shareholder Alert: Investigation over Possible Wrongdoing
↗
June 27, 2022
San Diego, CA -- (SBWIRE) -- 06/27/2022 -- Certain directors of Protagonist Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
3 Biotech Stocks to Buy Before They Boom
↗
June 01, 2022
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.
Via
InvestorPlace
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
↗
May 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
